A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2016
At a glance
- Drugs Ropinirole (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions; Registrational
- Sponsors GlaxoSmithKline
- 02 Nov 2012 Planned number of patients changed from 480 to 488 as reported by European Clinical Trials Database.
- 02 Nov 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2005-000184-25).
- 29 Jun 2012 Additional trial location added as reported by ClinicalTrials.gov.